Doxorubicin remains a cornerstone of front-line chemotherapy for breast cancer, lymphomas, sarcomas, and pediatric malignancies. With annual worldwide demand exceeding 11 million vials and liposomal formulations growing 8 % YoY, suppliers who can quickly identify qualified, regulation-ready buyers gain a decisive edge. This article delivers a curated, 2025-updated doxorubicin global buyers list, unpacks import-export trends, and provides an SEO-driven keyword map you can deploy immediately. 1. Why a Curated Buyers List Matters 2. 2025 Verified Doxorubicin Buyers by Region Data aggregated from TTV, Volza, and Cybex import manifests updated through July 2024; all companies below purchased ≥ 3 shipments in the last 12 months. North America Buyer City Main Formulation…